Last reviewed · How we verify
Vinorelbine Bitartrate
Vinorelbine bitartrate is a semi-synthetic vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in cancer cells.
Vinorelbine bitartrate is a semi-synthetic vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in cancer cells. Used for Non-small cell lung cancer (NSCLC), Breast cancer, Ovarian cancer.
At a glance
| Generic name | Vinorelbine Bitartrate |
|---|---|
| Sponsor | Zhejiang Hisun Pharmaceutical Co. Ltd. |
| Drug class | Vinca alkaloid; microtubule destabilizer |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vinorelbine bitartrate binds to β-tubulin and prevents microtubule polymerization, which disrupts the mitotic spindle formation necessary for cell division. This leads to cell cycle arrest in the G2/M phase and triggers programmed cell death in rapidly dividing cancer cells. The bitartrate salt form improves solubility and bioavailability compared to the free base.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Breast cancer
- Ovarian cancer
- Hodgkin lymphoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy (peripheral)
- Nausea/vomiting
- Fatigue
- Constipation
Key clinical trials
- Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer (PHASE3)
- Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |